The observed concomitant overexpression of BCL2 and BCL6 in the ARTD9 positive HR-subtype DLBCL cells also indicates that ARTD9 blocks the BCL6-mediated repression of BCL2 [470], which is frequently disrupted in DLBCL [365]. Here, PARP9 is linked to diffuse large B-cell lymphoma.